Monday, Sep 21, 2020 | Last Update : 03:25 AM IST

180th Day Of Lockdown

Maharashtra118801585793332216 Andhra Pradesh6177765307115302 Tamil Nadu5364774812738751 Karnataka5113454048417922 Uttar Pradesh3362942632884771 Delhi2347011981034877 West Bengal2155801870614183 Telangana1713061397001033 Odisha167161133466722 Bihar164224149722855 Assam150349121610528 Kerala12221687341490 Gujarat119088999083271 Rajasthan109088906851293 Haryana103773816901069 Madhya Pradesh97906743981877 Punjab90032658182646 Chhatisgarh7777541111628 Jharkhand6710052807590 Jammu and Kashmir5971138521951 Uttarakhand3713924810460 Goa2678320844327 Puducherry2142816253431 Tripura2069612956222 Himachal Pradesh11190691997 Chandigarh92566062106 Manipur8430653951 Arunachal Pradesh6851496713 Nagaland5306407910 Meghalaya4356234232 Sikkim2119178923 Mizoram15069490
  Metros   Delhi  14 Nov 2017  Cost of treatment of diabetes escalates due to high demand of insulin

Cost of treatment of diabetes escalates due to high demand of insulin

THE ASIAN AGE. | SHASHI BHUSHAN
Published : Nov 14, 2017, 2:24 am IST
Updated : Nov 14, 2017, 2:24 am IST

As per the study, sales of insulin have increased from Rs 218.7 crore to Rs 467.8 crore between 2012 and 2014.

The study aimed at sales trends of all top selling drugs for the past nine years, between 2008 and 2016, with emphasis on anti-diabetic drugs. (Photo: Pixabay)
 The study aimed at sales trends of all top selling drugs for the past nine years, between 2008 and 2016, with emphasis on anti-diabetic drugs. (Photo: Pixabay)

New Delhi: A recent study revealed that there has been a substantial escalation in the overall cost of treating diabetes in the country.

As per the study, sales of insulin have increased from Rs 218.7 crore to Rs 467.8 crore between 2012 and 2014. The study claimed primary reasons for this escalation includes reduced physicians’ tendency to prescribe insulin to diabetics, more diabetics having complications and aggressive marketing by pharmaceutical companies.

 

A study on the nationwide trends in the sales of anti-diabetic oral drugs and insulin was led by Dr Prof Anoop Misra, chairperson, Fortis C-DOC Hospital for Diabetes and Allied Specialities and president, National Diabetes Obesity and Cholesterol Foundation (N-DOC), The research aimed to study the sales trends of all top selling drugs (20 brands) for the past nine years (between Dec. 2008 and Dec. 2016), with emphasis on anti-diabetic drugs.

It found that from 2008 to 2012, sales of insulin increased from Rs 151.2 crore to Rs 218.7 crores (44 per cent growth).

“In this context, it is important to note that chronic kidney disease due to diabetes is more prevalent among Asian Indians, and increasingly being diagnosed, necessitating insulin therapy in several patients,” as per the study.

 

 According to the study, between 2014 and 2016, sales of insulin continued to see an upward trend from Rs 467.8 crore to Rs 842 crore (80 per cent increase) due to availability of new basal insulin and newer premix insulin to armamentarium.

“Our study shows that there is an escalation in the overall cost of treating diabetes in India. While there is also a rise in the usage of newer oral drugs and insulin analogues, affordability and accessibility of anti-diabetic therapy to socio-economic stratum remains inadequate.

India has to take several stringent measures to ensure that there is a balancing mechanism in place, education of physicians, tighter regulations on price control and stricter norms for pharmaceutical companies around new drugs and marketing ethics,” Dr Misra said.

 

Tags: diabetes, insulin